174774-98-2

Upstream product

• 2615-25-0 trans-1,4-cyclohexyldiamine 
• 76-83-5 trityl chloride 

Downstream Products

• 174775-06-5 tert-butyl trans-[4-(triphenylmethylamino)cyclohexylamino]acetate 
• 174775-37-2 trans-1-(n-butylamino)-4-(triphenylmethylamino)cyclohexane 
• 174775-39-4 [(4-{[5-(benzyloxycarbonylamino-imino-methyl)-benzofuran-2-carbonyl]-amino}-cyclohexyl)-butyl-amino]-acetic acid tert-butyl ester 
• 174774-29-9 tert-butyl trans-[4-(5-amidinobenzofuran-2-carboxamido)cyclohexyl-N-n-butylamino]acetate 
• 174775-07-6 tert-butyl trans-[4-(triphenylmethylamino)cyclohexyl-N-(tert-butoxycarbonyl)amino]acetate 
• 174775-38-3 tert-butyl trans-[4-(triphenylmethylamino)cyclohexyl-N-n-butylamino]acetate 
• 174775-36-1 tert-butyl trans-(4-aminocyclohexyl-N-n-butylamino)acetate 

Relevant academic research and scientific papers

Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 2. Condensed heterocyclic derivatives

A novel series of platelet receptor glycoprotein (Gp) IIb/IIIa antagonists with condensed heterocycles as their basic core was synthesized. In an in vitro assay, trans-4-(5-amidinobenzofuran-2- carboxamido)cyclohexyl]oxyacetic acid 17e and trans-3-[4-(5-

CARBOXYLIC ACID COMPOUND HAVING CONDENSED RING, SALT THEREOF AND PHARMACEUTICAL USE THEREOF

A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases